Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1477664
This article is part of the Research Topic Next Generation Therapeutic Modality to Cure Autoimmune Diseases View all 5 articles

Case report: Abrocitinib: a potential therapeutic option for lichen amyloidosis associated with atopic dermatitis

Provisionally accepted
Yizhen Zhang Yizhen Zhang 1,2Dawei Huang Dawei Huang 1,2Yunlu Gao Yunlu Gao 1,2*
  • 1 School of Medicine, Tongji University, Shanghai, Shanghai Municipality, China
  • 2 Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China

The final, formatted version of the article will be published soon.

    Lichen amyloidosis (LA) is a predominant type of primary cutaneous amyloidosis that is characterized by persistent and intense skin itching. Although multiple therapeutics strategies are available for its treatment, there is no standard treatment so far. Abrocitinib, an oral small-molecule Janus kinase 1 (JAK1) inhibitor, has been authorized for the treatment of severe atopic dermatitis (AD) and can also provide rapid relief from pruritus. Here, we discuss the case of a 32-year-old man who was diagnosed with LA with severe AD based on the presence of multiple, discrete, and hyperpigmented papules and pruritic, erythematous macules with lichenification of the limbs, trunk, and buttocks. Given the inefficacy of conventional therapy, abrocitinib treatment was recommended in this patient.After one month of treatment, the patient's EASI score decreased significantly from 48 to 15 points, accompanied by a notable reduction in pruritus symptoms. Furthermore, significant improvements were observed in the thickness and pigmentation of the hyperkeratotic papules. Thus, abrocitinib exhibited excellent effectiveness and safety in the treatment of severe AD with LA and warrants further investigation for its potential therapeutic benefits.

    Keywords: Abrocitinib, atopic dermatitis, Lichen amyloidosis, Small molecule drugs, case report

    Received: 08 Aug 2024; Accepted: 17 Oct 2024.

    Copyright: © 2024 Zhang, Huang and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yunlu Gao, Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.